Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.

Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Dunnmon PM, Pratt CM, Holroyde MJ, Kowey P; Shock Inhibition Evaluation with Azimilide Investigators.

J Am Coll Cardiol. 2008 Sep 23;52(13):1076-83. doi: 10.1016/j.jacc.2008.05.055.

2.

Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator.

Pratt CM, Dorian P, Al-Khalidi HR, Brum JM, Borggrefe M, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, Holroyde MJ, van der Laan M, Hohnloser SH; SHIELD Investigators.

Am J Cardiol. 2005 Jan 15;95(2):274-6.

PMID:
15642569
3.

Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.

Robinson VM, Bharucha DB, Mahaffey KW, Dorian P, Kowey PR; SHIELD-2 Investigators.

Am Heart J. 2017 Mar;185:43-51. doi: 10.1016/j.ahj.2016.10.025. Epub 2016 Nov 15.

4.

Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM; SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators.

Circulation. 2004 Dec 14;110(24):3646-54. Epub 2004 Nov 8.

5.

Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.

Bollmann A, Husser D, Cannom DS.

Am J Cardiovasc Drugs. 2005;5(6):371-8. Review.

PMID:
16259525
6.

Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.

Pratt CM, Al-Khalidi HR, Brum JM, Holroyde MJ, Schwartz PJ, Marcello SR, Borggrefe M, Dorian P, Camm AJ; Azimilide Trials Investigators.

J Am Coll Cardiol. 2006 Aug 1;48(3):471-7. Epub 2006 Jul 12.

7.
8.

Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.

Singer I, Al-Khalidi H, Niazi I, Tchou P, Simmons T, Henthorn R, Holroyde M, Brum J.

J Am Coll Cardiol. 2004 Jan 7;43(1):39-43.

9.

The azimilide post-infarct survival evaluation (ALIVE) trial.

Camm AJ, Karam R, Pratt CM.

Am J Cardiol. 1998 Mar 19;81(6A):35D-39D.

PMID:
9537221
10.

Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.

Pritchett EL, Kowey P, Connolly S, Page RL, Kerr C, Wilkinson WE; A-COMET-I Investigators.

Am Heart J. 2006 May;151(5):1043-9.

PMID:
16644334
11.

Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.

Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE.

J Am Coll Cardiol. 2000 Sep;36(3):794-802.

12.

Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.

Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM; AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators.

Circulation. 2004 Mar 2;109(8):990-6. Epub 2004 Feb 16.

13.

Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial.

Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P, Dorian P; SHock Inhibition Evaluation with AzimiLiDe (SHIELD) Investigators.

Eur Heart J. 2006 Dec;27(24):3027-32. Epub 2006 Oct 18.

PMID:
17050586
14.

Azimilide for atrial fibrillation: clinical trial results and implications.

Pritchett EL, Marcello SR.

Card Electrophysiol Rev. 2003 Sep;7(3):215-9. Review.

PMID:
14739716
15.

Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works.

Cannom DS, Gidney B.

J Am Coll Cardiol. 2008 Sep 23;52(13):1084-5. doi: 10.1016/j.jacc.2008.07.003. No abstract available.

16.

Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions.

Gojkovic O, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Singh BN, Kowey PR.

Heart Rhythm. 2012 Feb;9(2):217-224.e2. doi: 10.1016/j.hrthm.2011.09.073. Epub 2011 Oct 4.

PMID:
21978965
17.

The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.

Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, Schwartz PJ, Camm AJ; ALIVE Investigators.

J Am Coll Cardiol. 2004 Apr 7;43(7):1211-6.

18.

Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials.

Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL; Azimilide Supraventricular Arrhythmia Program Investigators.

Am Heart J. 2003 Sep;146(3):489-93.

PMID:
12947368
19.

The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.

Wilkoff BL; Dual Chamber and VVI Implantable Defibrillator trial investigators.

Card Electrophysiol Rev. 2003 Dec;7(4):468-72.

PMID:
15071277
20.

Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation.

Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL.

Am J Cardiol. 2001 Nov 1;88(9):974-9.

PMID:
11703992

Supplemental Content

Support Center